XML 380 R53.htm IDEA: XBRL DOCUMENT
v3.26.1

Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS (Details) € in Thousands, $ in Millions |  | 1 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Dec. 05, 2025 EUR (€) item | Dec. 05, 2025 USD ($) | Dec. 31, 2025 USD ($) | Mar. 31, 2025 USD ($) | Dec. 31, 2025 EUR (€) | Dec. 31, 2024 EUR (€) | Dec. 05, 2025 USD ($) item
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS |  |  |  |  |  |  |
Proceeds from disposal of subsidiaries |  |  |  |  | € 222,333 | € (11,503) |
Receivable for additional purchase price payment |  |  |  |  | 12,161 |  |
Just-Evotec Biologics EU SAS, Toulouse, France |  |  |  |  |  |  |
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS |  |  |  |  |  |  |
Percentage of ownership interest in subsidiary sold | 100.00% | 100.00% |  |  |  |  |
Enterprise value | € 225,000 |  |  |  |  |  |
Purchase price | 152,959 |  |  |  |  |  |
Intercompany loans settled by buyer as part of consideration for sale of subsidiary | 84,000 |  |  |  |  |  |
Gain (loss) on disposal of subsidiary | € (3,750) |  |  |  |  |  |
Licence revenue | $ |  |  | $ 108 | $ 25 |  |  |
New license agreement upfront license fee received | $ |  | $ 58 |  |  |  |  |
Maximum number of biosimilars on which agreement foresees royalties | item | 10 |  |  |  |  |  | 10
Proceeds from disposal of subsidiaries | € 222,649 |  |  |  |  |  |
Intercompany loan settlement included in proceeds from disposal of subsidiaries | € 84,000 |  |  |  |  |  |
Receivable for additional purchase price payment |  |  |  |  | € 12,161 |  |
Just-Evotec Biologics EU SAS, Toulouse, France | Payable in 60 days after closing |  |  |  |  |  |  |
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS |  |  |  |  |  |  |
New license agreement license fees to be received | $ |  |  |  |  |  |  | $ 25
Just-Evotec Biologics EU SAS, Toulouse, France | Payable in December 2026 |  |  |  |  |  |  |
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS |  |  |  |  |  |  |
New license agreement license fees to be received | $ |  |  |  |  |  |  | 25
Just-Evotec Biologics EU SAS, Toulouse, France | Payable over coming years |  |  |  |  |  |  |
Significant transactions - Completion of the disposal of Just Evotec Biologics EU SAS |  |  |  |  |  |  |
New license agreement license fees to be received | $ |  |  |  |  |  |  | $ 300

X
- Definition Consideration for sale of subsidiary + References No definition available. + Details
Name: | evo_ConsiderationForSaleOfSubsidiary
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of enterprise value, calculated on cash and debt free basis. + References No definition available. + Details
Name: | evo_EnterpriseValue
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Intercompany loan settlement included in proceeds from disposal of subsidiaries + References No definition available. + Details
Name: | evo_IntercompanyLoanSettlementIncludedInProceedsFromDisposalOfSubsidiaries
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liabilities settled, included as a part of consideration on sale of disposal group. + References No definition available. + Details
Name: | evo_LiabilitiesSettledConsiderationForDisposalGroup
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum number of biosimilars on which agreement foresees royalties + References No definition available. + Details
Name: | evo_MaximumNumberOfBiosimilarsOnWhichAgreementForeseesRoyalties
Namespace Prefix: | evo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition New license agreement license fees to be received + References No definition available. + Details
Name: | evo_NewLicenseAgreementLicenseFeesToBeReceived
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition New license agreement upfront license fee received + References No definition available. + Details
Name: | evo_NewLicenseAgreementUpfrontLicenseFeeReceived
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary sold during the period. + References No definition available. + Details
Name: | evo_ProportionOfOwnershipInterestInSubsidiarySold
Namespace Prefix: | evo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of receivables arising from the sale of subsidiaries. + References No definition available. + Details
Name: | evo_ReceivablesFromSaleOfSubsidiary
Namespace Prefix: | evo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate cash flows arising from losing control of subsidiaries or other businesses, classified as investing activities. [Refer: Total for all subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2025-01-01 -Paragraph 39 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_CashFlowsFromLosingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The gains (losses) recognised in association with the loss of control over a subsidiary, which are attributable to the former controlling interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2025-01-01 -Paragraph 19 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard -URIDate 2025-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 81 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard -URIDate 2025-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective 2027-01-01 -Name IFRS -Number 19 -IssueDate 2025-01-01 -Paragraph 81 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_81&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_GainsLossesRecognisedWhenControlInSubsidiaryIsLost
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Note Expiry date 2027-01-01 -Name IAS -Number 1 -IssueDate 2025-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_LicenceFeeIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=evo_JustEvotecBiologicsEuSasToulouseFranceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=evo_PayableIn60DaysAfterClosingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=evo_PayableInDecember2026Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=evo_PayableOverComingYearsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |